258 related articles for article (PubMed ID: 33141777)
21. Coagulation assay discrepancies in Japanese patients with non-severe hemophilia A.
Inaba H; Nishikawa S; Shinozawa K; Shinohara S; Nakazawa F; Amano K; Kinai E
Int J Hematol; 2022 Feb; 115(2):173-187. PubMed ID: 34751920
[TBL] [Abstract][Full Text] [Related]
22. In silico and in vitro evaluation of the impact of mutations in non-severe haemophilia A patients on assay discrepancies.
Pezeshkpoor B; Gazorpak M; Berkemeier AC; Singer H; Pavlova A; Biswas A; Oldenburg J
Ann Hematol; 2019 Aug; 98(8):1855-1865. PubMed ID: 30997536
[TBL] [Abstract][Full Text] [Related]
23. Factor VIII: C (FVIII: C) recovery and half-life after infusion of steam-treated high purity factor VIII concentrate in severe hemophilia A--comparison of one-stage assay, two-stage assay and a chromogenic substrate assay.
Hellstern P; Kiehl R; Miyashita C; Schwerdt H; von Blohn G; Köhler M; Büttner M; Wenzel E
Thromb Haemost; 1986 Dec; 56(3):353-9. PubMed ID: 3105109
[TBL] [Abstract][Full Text] [Related]
24. Discrepant Hemophilia A: An Underdiagnosed Disease Entity.
Al-Huniti A; Sharathkumar A; Krantz M; Watkinson K; Bhagavathi S
Am J Clin Pathol; 2020 Jun; 154(1):78-87. PubMed ID: 32232366
[TBL] [Abstract][Full Text] [Related]
25. Tyr346-->Cys mutation results in factor VIII:C assay discrepancy and a normal bleeding phenotype - is this mild haemophilia A?
Lyall H; Hill M; Westby J; Grimley C; Dolan G
Haemophilia; 2008 Jan; 14(1):78-80. PubMed ID: 18034822
[TBL] [Abstract][Full Text] [Related]
26. Specific and global coagulation assays in the diagnosis of discrepant mild hemophilia A.
Bowyer AE; Van Veen JJ; Goodeve AC; Kitchen S; Makris M
Haematologica; 2013 Dec; 98(12):1980-7. PubMed ID: 23812942
[TBL] [Abstract][Full Text] [Related]
27. Assay discrepancy in mild haemophilia A: entire population study in a National Haemophilia Centre.
Poulsen AL; Pedersen LH; Hvas AM; Poulsen LH; Thykjaer H; Ingerslev J
Haemophilia; 2009 Jan; 15(1):285-9. PubMed ID: 19149854
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of Chromogenic Factor VIII Assay Compared with One-Stage Clotting Assay.
Akkaya E; Hatiboglu S; Koc B; Genc S; Unuvar A; Karaman S; Omer B; Karakas Z; Zulfikar B
Clin Lab; 2020 Oct; 66(10):. PubMed ID: 33073956
[TBL] [Abstract][Full Text] [Related]
29. Impact of variation in reagent combinations for one-stage clotting assay on assay discrepancy in nonsevere haemophilia A.
Suzuki A; Suzuki N; Kanematsu T; Okamoto S; Tamura S; Kikuchi R; Katsumi A; Kiyoi H; Kojima T; Matsushita T
Int J Lab Hematol; 2021 Feb; 43(1):131-138. PubMed ID: 32915508
[TBL] [Abstract][Full Text] [Related]
30. Mild hemophilia A with factor VIII assay discrepancy: using thrombin generation assay to assess the bleeding phenotype.
Trossaërt M; Regnault V; Sigaud M; Boisseau P; Fressinaud E; Lecompte T
J Thromb Haemost; 2008 Mar; 6(3):486-93. PubMed ID: 18047548
[TBL] [Abstract][Full Text] [Related]
31. Chromogenic assay for BAY 81-8973 potency assignment has no impact on clinical outcome or monitoring in patient samples.
Kitchen S; Katterle Y; Beckmann H; Maas Enriquez M
J Thromb Haemost; 2016 Jun; 14(6):1192-9. PubMed ID: 27002680
[TBL] [Abstract][Full Text] [Related]
32. Analytical variation in factor VIII one-stage and chromogenic assays: Experiences from the ECAT external quality assessment programme.
van Moort I; Meijer P; Priem-Visser D; van Gammeren AJ; Péquériaux NCV; Leebeek FWG; Cnossen MH; de Maat MPM
Haemophilia; 2019 Jan; 25(1):162-169. PubMed ID: 30488994
[TBL] [Abstract][Full Text] [Related]
33. Assessing the Performance of Extended Half-Life Coagulation Factor VIII, FC Fusion Protein by Using Chromogenic and One-Stage Assays in Saudi Hemophilia A Patients.
Owaidah TM; Alzahrani HA; Al-Numair NS; Alnosair AO; Aguilos AM; Saleh M
Adv Hematol; 2020; 2020():8768074. PubMed ID: 32963537
[TBL] [Abstract][Full Text] [Related]
34. Discrepancy between one-stage and chromogenic factor VIII activity assay results can lead to misdiagnosis of haemophilia A phenotype.
Oldenburg J; Pavlova A
Hamostaseologie; 2010 Nov; 30(4):207-11. PubMed ID: 21057709
[TBL] [Abstract][Full Text] [Related]
35. Validation of a procedure for potency assessing of a high purity factor VIII concentrate--comparison of different factor VIII coagulant assays and effect of prediluent.
Mazurier C; Parquet-Gernez A; Goudemand M
Thromb Haemost; 1990 Oct; 64(2):251-5. PubMed ID: 2125374
[TBL] [Abstract][Full Text] [Related]
36. Treatment changes in hemophilia A with chromogenic factor VIII assay implementation.
Al Moosawi M; Nicolson H; Wong SKW; Dallas KL; Jackson S
Res Pract Thromb Haemost; 2023 Feb; 7(2):100098. PubMed ID: 37063773
[TBL] [Abstract][Full Text] [Related]
37. Performance of recalibrated ReFacto laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one-stage assays after infusion of recalibrated ReFacto (B-domain deleted recombinant factor VIII).
Santoro C; Iorio A; Ferrante F; Pallotta A; Pignoloni P; Biondo F; Agnelli G; Mazzucconi MG
Haemophilia; 2009 May; 15(3):779-87. PubMed ID: 19298379
[TBL] [Abstract][Full Text] [Related]
38. Cross-reacting Material-positive Hemophilia A Diagnosed in a Patient with a Spontaneous Thigh Hemorrhage.
Saito T; Mukae J; Nakamura Y; Inaba H; Nogami K; Koyama T; Fukutake K; Yamamoto K
Intern Med; 2017; 56(13):1719-1723. PubMed ID: 28674365
[TBL] [Abstract][Full Text] [Related]
39. Factor VIII chromogenic assays can be used for potency labeling and postadministration monitoring of N8-GP.
Pickering W; Hansen M; Kjalke M; Ezban M
J Thromb Haemost; 2016 Aug; 14(8):1579-87. PubMed ID: 27241682
[TBL] [Abstract][Full Text] [Related]
40. Agreement between one stage and chromogenic assays in samples from patients receiving recombinant porcine FVIII (Obizur, Susoctocog-alfa).
Guy S; Bowyer AE; Shepherd MF; Maclean RM; Kitchen S
Int J Lab Hematol; 2024 Feb; 46(1):135-140. PubMed ID: 37799011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
